검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Selumetinib |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target poor prognosis KMT2A-rearranged RAS pathway |
MoA Biomarker | EGFR)-mutated advanced non-small cell lung cancer (NSCLC) follow |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.. ORCHARD (NCT03944772) was a phase II, biomarker-matched, platform study designed to characterise resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung … |
Clinical Primary efficacy | ORR 19.7% |
Clinical ORR | 19.7% |
Clinical Result source | ClinicalTrials.gov NCT04924608 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Selumetinib |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target poor prognosis KMT2A-rearranged RAS pathway |
MoA Biomarker | EGFR)-mutated advanced non-small cell lung cancer (NSCLC) follow |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.. ORCHARD (NCT03944772) was a phase II, biomarker-matched, platform study designed to characterise resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung … |
Clinical Primary efficacy | ORR 19.7% |
Clinical ORR | 19.7% |
Clinical Result source | ClinicalTrials.gov NCT04924608 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교